Modified radiation lobectomy as a bridge to curative surgery: tumor response, future liver remnant hypertrophy, and surgical outcomes
Abstract
Few studies support modified radiation lobectomy (mRL) as a bridge to curative resection. This retrospective study reviews outcomes after mRL. Patients with primary hepatic tumors undergoing mRL 90Y radioembolization to grow the future liver remnant (FLR) were reviewed. Outcomes included tumor response, FLR kinetics, tumor progression, surgical conversion, and pathologic outcomes. Fifteen patients (7 women, 8 men; mean age 66) with hepatocellular carcinoma (HCC, n = 7) and intrahepatic cholangiocarcinoma (ICC, n = 8) with mean tumor size 7.8 ± 3.7 cm were included. HCC patients were intermediate (BCLC B, n = 6) or advanced (BCLC C, n = 1) stage. No severe adverse events occurred. All patients had initial objective response at 30 days: 40% complete response, 60% partial response. Median FLR increased by 12% at 30 days and 30% at 90 days. Twelve patients (80%) became technically eligible for curative-intent surgery. Ultimately, 10 underwent major hepatectomy (n = 9) or transplant (n = 1) all with negative margins, at a mean of 122 ± 77 days post-treatment. Despite variable rates of pathologic necrosis, overall survival remained 80% after surgery. Large primary hepatic tumors can be down-staged with mRL, promoting sufficient liver remnant hypertrophy while controlling tumor progression, suggesting that mRL may facilitate curative-intent surgery in carefully selected patients.